Covidien Plc. (NYSE:COV) won an appeal of a trial judge’s decision to back Becton Dickinson and Company’s (NYSE:BDX) patent infringement claim.
The U.S. Court of Appeals for the Federal Circuit in Washington on Thursday tossed the $58 million damage award against the Mansfield, Mass. based medical products conglomerate, formerly Tyco Healthcare, over safety syringes.
The 2-1 decision reversed the former ruling that found Covidien‘s Monoject Magellan syringes infringed on a BD patent.
The Franklin Lakes, N.J.-based BD is still considering its options, according to reports.
Covidien yesterday announced a $364 million profit on 2.6 billion in sales for the second quarter.
BD yesterday said that its profits dropped 10 percent during the third quarter.